368 related articles for article (PubMed ID: 11157038)
1. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.
Gordon MS; Margolin K; Talpaz M; Sledge GW; Holmgren E; Benjamin R; Stalter S; Shak S; Adelman D
J Clin Oncol; 2001 Feb; 19(3):843-50. PubMed ID: 11157038
[TBL] [Abstract][Full Text] [Related]
2. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data.
Margolin K; Gordon MS; Holmgren E; Gaudreault J; Novotny W; Fyfe G; Adelman D; Stalter S; Breed J
J Clin Oncol; 2001 Feb; 19(3):851-6. PubMed ID: 11157039
[TBL] [Abstract][Full Text] [Related]
3. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor.
Lin YS; Nguyen C; Mendoza JL; Escandon E; Fei D; Meng YG; Modi NB
J Pharmacol Exp Ther; 1999 Jan; 288(1):371-8. PubMed ID: 9862791
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans.
Mordenti J; Thomsen K; Licko V; Chen H; Meng YG; Ferrara N
Toxicol Pathol; 1999; 27(1):14-21. PubMed ID: 10367667
[TBL] [Abstract][Full Text] [Related]
5. Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer.
Jayson GC; Mulatero C; Ranson M; Zweit J; Jackson A; Broughton L; Wagstaff J; Hakansson L; Groenewegen G; Lawrance J; Tang M; Wauk L; Levitt D; Marreaud S; Lehmann FF; Herold M; Zwierzina H;
Eur J Cancer; 2005 Mar; 41(4):555-63. PubMed ID: 15737560
[TBL] [Abstract][Full Text] [Related]
6. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies.
Jayson GC; Zweit J; Jackson A; Mulatero C; Julyan P; Ranson M; Broughton L; Wagstaff J; Hakannson L; Groenewegen G; Bailey J; Smith N; Hastings D; Lawrance J; Haroon H; Ward T; McGown AT; Tang M; Levitt D; Marreaud S; Lehmann FF; Herold M; Zwierzina H;
J Natl Cancer Inst; 2002 Oct; 94(19):1484-93. PubMed ID: 12359857
[TBL] [Abstract][Full Text] [Related]
7. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors.
Thomas JP; Arzoomanian RZ; Alberti D; Marnocha R; Lee F; Friedl A; Tutsch K; Dresen A; Geiger P; Pluda J; Fogler W; Schiller JH; Wilding G
J Clin Oncol; 2003 Jan; 21(2):223-31. PubMed ID: 12525513
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
Pegram MD; Lipton A; Hayes DF; Weber BL; Baselga JM; Tripathy D; Baly D; Baughman SA; Twaddell T; Glaspy JA; Slamon DJ
J Clin Oncol; 1998 Aug; 16(8):2659-71. PubMed ID: 9704716
[TBL] [Abstract][Full Text] [Related]
9. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration.
Mordenti J; Cuthbertson RA; Ferrara N; Thomsen K; Berleau L; Licko V; Allen PC; Valverde CR; Meng YG; Fei DT; Fourre KM; Ryan AM
Toxicol Pathol; 1999; 27(5):536-44. PubMed ID: 10528633
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
Baselga J; Tripathy D; Mendelsohn J; Baughman S; Benz CC; Dantis L; Sklarin NT; Seidman AD; Hudis CA; Moore J; Rosen PP; Twaddell T; Henderson IC; Norton L
J Clin Oncol; 1996 Mar; 14(3):737-44. PubMed ID: 8622019
[TBL] [Abstract][Full Text] [Related]
11. Wide spectrum of antitumor activity of a neutralizing monoclonal antibody to human vascular endothelial growth factor.
Asano M; Yukita A; Suzuki H
Jpn J Cancer Res; 1999 Jan; 90(1):93-100. PubMed ID: 10076571
[TBL] [Abstract][Full Text] [Related]
12. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
Jain RK
Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
[TBL] [Abstract][Full Text] [Related]
13. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3.
Gutheil JC; Campbell TN; Pierce PR; Watkins JD; Huse WD; Bodkin DJ; Cheresh DA
Clin Cancer Res; 2000 Aug; 6(8):3056-61. PubMed ID: 10955784
[TBL] [Abstract][Full Text] [Related]
14. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.
Ferrara N
Semin Oncol; 2002 Dec; 29(6 Suppl 16):10-4. PubMed ID: 12516033
[TBL] [Abstract][Full Text] [Related]
15. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor.
Gerber HP; Kowalski J; Sherman D; Eberhard DA; Ferrara N
Cancer Res; 2000 Nov; 60(22):6253-8. PubMed ID: 11103779
[TBL] [Abstract][Full Text] [Related]
16. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis.
McCrudden KW; Hopkins B; Frischer J; Novikov A; Huang J; Kadenhe A; New T; Yokoi A; Yamashiro DJ; Kandel JJ; Middlesworth W
J Pediatr Surg; 2003 Mar; 38(3):308-14; discussion 308-14. PubMed ID: 12632340
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of rhuMAb CD18, a recombinant humanised monoclonal antibody fragment to CD18, in normal healthy human volunteers.
Allison DE; Gourlay SG; Koren E; Miller RM; Fox JA
BioDrugs; 2002; 16(1):63-70. PubMed ID: 11968154
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121.
Asano M; Yukita A; Matsumoto T; Kondo S; Suzuki H
Cancer Res; 1995 Nov; 55(22):5296-301. PubMed ID: 7585591
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model.
Melnyk O; Zimmerman M; Kim KJ; Shuman M
J Urol; 1999 Mar; 161(3):960-3. PubMed ID: 10022734
[TBL] [Abstract][Full Text] [Related]
20. Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer.
Fox WD; Higgins B; Maiese KM; Drobnjak M; Cordon-Cardo C; Scher HI; Agus DB
Clin Cancer Res; 2002 Oct; 8(10):3226-31. PubMed ID: 12374693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
